• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Nature's Sunshine Products Inc.

    6/20/25 3:07:31 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001236872
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    NATURES SUNSHINE PRODUCTS INC
    SEC File Number
    001-34483
    Address of Issuer
    2901 WEST BLUEGRASS BLVD.
    SUITE 100
    LEHI
    UTAH
    84043
    Phone
    (801) 341-7900
    Name of Person for Whose Account the Securities are To Be Sold
    MOSS RICHARD D
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Wells Fargo Clearing Services
    One North Jefferson Avenue
    St. Louis � MO � 63103
    150021921.731835080106/20/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/02/2025Restricted Share Grants and CompensationIssuerCheckbox not checked150005/02/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Nature's Sunshine Products, Inc.05/09/202510000137426.61
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Nature's Sunshine Products, Inc.05/12/2025500072658.80
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Nature's Sunshine Products, Inc.05/14/20252503531.25
    Richard D Moss Revocable Trust
    2901Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Natures's Sunshine Products, Inc.05/15/202575010889.15
    Richard D Moss
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Nature's Sunshine Products, Inc.05/16/2025250036838.53
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Nature's Sunshine Products, Inc.05/19/2025300044315.16
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Nature's Sunshine Products, Inc.05/22/20255007203.26
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Nature's Sunshine Products, Inc.05/27/2025300044263.22
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Natures Sunshine Products, Inc.05/29/2025550082634.84
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Natures Sunshine Products, Inc.06/03/2025100014528.00
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Natures Sunshine Products, Inc.06/13/202573410606.90
    Richard D Moss Revocable Trust
    2901 Bluegrass Boulevard, Suite 100
    Lehi � UT � 84043
    Natures Sunshine Products, Inc.06/18/2025100014527.23

    144: Remarks and Signature

    Remarks
    The shares were sold from the Richard D Moss Revocable Trust.
    Date of Notice
    06/20/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Richard D Moss

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NATR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & President, Europe Yates Bryant J covered exercise/tax liability with 1,738 shares, decreasing direct ownership by 2% to 107,170 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      7/23/25 4:13:28 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Global Supply Chain Gonzalez Martin A. covered exercise/tax liability with 3,781 shares, decreasing direct ownership by 5% to 65,518 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      7/23/25 4:13:20 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Moorehead Terrence covered exercise/tax liability with 9,302 shares, decreasing direct ownership by 2% to 543,292 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      7/23/25 4:13:11 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    SEC Filings

    See more
    • Nature's Sunshine Products Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      7/7/25 4:17:43 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Nature's Sunshine Products Inc.

      8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      6/27/25 8:31:04 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Nature's Sunshine Products Inc.

      424B5 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      6/27/25 7:23:14 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DA Davidson resumed coverage on Nature's Sunshine with a new price target

      DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

      5/7/25 8:37:48 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

      Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

      9/13/24 7:38:59 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

      DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

      3/9/22 9:23:08 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nature's Sunshine Sets Second Quarter 2025 Conference Call for Thursday, July 31, 2025, at 5:00 p.m. ET

      LEHI, Utah, July 17, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, July 31, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the second quarter ended June 30, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, July 31, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-fr

      7/17/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Products, Inc. Announces Pricing of Secondary Public Offering of Common Stock

      LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the "Selling Stockholder"). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions. The Selling Stockholder will receive all of the net proceeds from the offering. Nature's Sunshine is not selling any shares of common stoc

      6/26/25 6:30:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Products, Inc. Announces Launch of Secondary Public Offering of Common Stock

      LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the "Selling Stockholder"). The Selling Stockholder will receive all of the net proceeds from the offering. Nature's Sunshine is not selling any shares of common stock in the offering and will not receive any proceeds from the offering. The Selling Stockholder will pay any underwriting discounts and commissions and transfer taxes at

      6/25/25 4:01:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Financials

    Live finance-specific insights

    See more
    • Nature's Sunshine Sets Second Quarter 2025 Conference Call for Thursday, July 31, 2025, at 5:00 p.m. ET

      LEHI, Utah, July 17, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, July 31, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the second quarter ended June 30, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, July 31, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-fr

      7/17/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Reports Strong First Quarter 2025 Results

      LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

      5/6/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Sets First Quarter 2025 Conference Call for Tuesday, May 6, 2025, at 5:00 p.m. ET

      LEHI, Utah, April 22, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, May 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, May 6, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-free di

      4/22/25 4:04:59 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/12/24 10:37:49 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      1/31/24 11:56:05 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/13/23 2:42:04 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    See more
    • Nature's Sunshine Announces Leadership Transition Plan

      Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors. The Nature's Sunshine Board ha

      6/2/25 9:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

      LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

      5/5/25 8:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Katie A. May to Board of Directors

      LEHI, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Ms. Katie A. May to its board of directors effective January 30, 2025. Nature's Sunshine's board will now consist of ten directors with nine serving as independent directors. "Katie brings significant experience scaling and leading high-growth B2C, ecommerce and logistics companies," said Richard D. Moss, Chairman of the Board of Nature's Sunshine. "Her deep understanding of the full ecommerce lifecycle will strengthen and enhance our digital capabilities and drive s

      2/5/25 4:05:00 PM ET
      $NATR
      $PBI
      $STMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Office Equipment/Supplies/Services
      Miscellaneous